Benzinga | Sep 21, 2020 11:44AM EDT

Northland Capital Markets Upgrades Pacira BioSciences to Outperform, Raises Price Target to $67

Northland Capital Markets analyst Tim Chiang upgrades Pacira BioSciences (NASDAQ:PCRX) from Market Perform to Outperform and raises the price target from $58 to $67.